samarium and melphalan
samarium has been researched along with melphalan in 5 studies
Research
Studies (5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Berger, JD; Claringbold, PG; Glancy, RJ; Manning, LS; O'Donoghue, HL; Turner, JH | 1 |
| Bares, R; Dohmen, BM; Einsele, H; Kanz, L; Knop, S | 1 |
| Anderson, PM; Ansell, SM; Dispenzieri, A; Elliott, MA; Erlichman, C; Fonseca, R; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Lacy, MQ; Litzow, MR; Lust, JA; Micallef, IN; Porrata, L; Rajkumar, SV; Sloan, JA; Tefferi, A; Wiseman, GA; Witzig, TE | 1 |
| Anderson, PM; Arndt, CA; Erlandson, L; Rodriguez, V; Wiseman, GA | 1 |
| Allred, J; Ansell, SM; Buadi, F; Dingli, D; Dispenzieri, A; Elliott, MA; Gastineau, DA; Gertz, MA; Geyer, SM; Hayman, SR; Hogan, WJ; Inwards, DJ; Johnston, PB; Kumar, SK; Lacy, MQ; Laumann, KM; Litzow, MR; Micallef, IN; Porrata, L; Wiseman, GA | 1 |
Trials
2 trial(s) available for samarium and melphalan
| Article | Year |
|---|---|
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Radioisotopes; Samarium; Stem Cell Transplantation; Tissue Distribution; Transplantation Conditioning | 2005 |
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Topics: Adult; Aged; Bone Marrow; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Organometallic Compounds; Organophosphorus Compounds; Pain; Peripheral Blood Stem Cell Transplantation; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Salvage Therapy; Samarium; Tissue Distribution; Transplantation Conditioning | 2010 |
Other Studies
3 other study(ies) available for samarium and melphalan
| Article | Year |
|---|---|
Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatment with samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Combined Modality Therapy; Female; In Vitro Techniques; Male; Melphalan; Mice; Mice, Inbred C57BL; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Samarium; Survival Analysis; Tumor Cells, Cultured | 1993 |
153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma.
Topics: Fatal Outcome; Graft Survival; Humans; Male; Melphalan; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Osteolysis; Peripheral Blood Stem Cell Transplantation; Radioisotopes; Radiopharmaceuticals; Salvage Therapy; Samarium; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.
Topics: Adolescent; Female; Humans; Leukemia, Myeloid, Acute; Melphalan; Organometallic Compounds; Organophosphorus Compounds; Radioisotopes; Samarium; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2005 |